Lee's Pharmaceutical HoldingsLPCUF 72 EV-to-FCF is 4.22 as of Jul. 08, 2026, which is 73% below its 10-year median of 15.75. GuruFocus rates LPCUF with a GF Score™ of 72/100 and a GF Value™ of $0.30. The stock has 5 warning signs investors should review. Among 563 Drug Manufacturers companies, Lee's Pharmaceutical Holdings ranks better than 90.94% on this metric.
The historical rank and industry rank for Lee's Pharmaceutical Holdings's EV-to-FCF or its related term are showing as below:
LPCUF'
s EV-to-FCF Range Over the Past 10 Years
Min: -53.55 Med: 15.75 Max: 264.86
Current: 4.22
During the past 13 years, the highest EV-to-FCF of Lee's Pharmaceutical Holdings was 264.86. The lowest was -53.55. And the median was 15.75.
LPCUF's EV-to-FCF is ranked better than 90.94% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs LPCUF: 4.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lee's Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:
Lee's Pharmaceutical Holdings's share price for today is $0.1903.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lee's Pharmaceutical Holdings EV-to-FCF Related Terms
Lee's Pharmaceutical Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's EV-to-FCF falls into.
Lee's Pharmaceutical Holdings's current Enterprise Value is $54.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $12.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (LPCUF) has a EV-to-FCF of 4.22 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lee's Pharmaceutical Holdings and its competitors. This is 73% below median its historical median of 15.75. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #51 out of 563 companies in the Drug Manufacturers industry, placing it in the top 9.1%.
Is Lee's Pharmaceutical Holdings' EV-to-FCF too high?
Lee's Pharmaceutical Holdings' current EV-to-FCF of 4.22 is 73% below median its 10-year median of 15.75. The Drug Manufacturers industry median EV-to-FCF is 20.85. Lee's Pharmaceutical Holdings' value of 4.22 is 79.8% below this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #51 out of 563 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #51 out of 563 companies for EV-to-FCF. This places Lee's Pharmaceutical Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.85. Lee's Pharmaceutical Holdings' value of 4.22 is 79.8% below this benchmark. While the company's 10-year median is 15.75 vs. the industry median of 20.85, Lee's Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current EV-to-FCF of 4.22 is 79.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lee's Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current EV-to-FCF is 4.22, which is 73% below median its own 10-year median of 15.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (LPCUF) has a current EV-to-FCF of 4.22. The stock's GF Value™ is $0.30, compared to a current price of $0.19 — trading 36.6% below its estimated fair value. The current EV-to-FCF is 4.22, which is 73% below median its 10-year median of 15.75 and 79.8% below the Drug Manufacturers industry median of 20.85. Lee's Pharmaceutical Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (LPCUF), the current EV-to-FCF is 4.22 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of $0.19 is trading 36.6% below its estimated GF Value™ of $0.30.
Key valuation signals for LPCUF:
EV-to-FCF: 4.22 (73% below median its 10-year median of 15.75)
GF Value™: $0.30 vs. price of $0.19 (36.6% below fair value)
Industry Position: 79.8% below the Drug Manufacturers median (#51 of 563)
No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
72GF Score
Get the complete analysis for LPCUF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCUF has been successfully added to your 
